Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Intravesical mitomycin C is an effective agent for treatment of superficial transitional cell carcinoma of the bladder. A 60 to 70 per cent overall response rate has been reported. Its side effects have been minor. We present a case of severe bladder contracture after intravesical therapy with mitomycin C.
D000283:Administration, Intravesical; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003286:Contracture / Q000139:chemically induced; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects*; D001745:Urinary Bladder Diseases / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D008937:Mitomycins; D016685:Mitomycin